<?xml version="1.0" encoding="UTF-8"?>

<rootTag>
  <Award>
    <AwardTitle>SBIR Phase II: Clinical-Scale Suspension Bioreactor for Primary Hematopoietic Culture</AwardTitle>
    <AwardEffectiveDate>12/01/2000</AwardEffectiveDate>
    <AwardExpirationDate>02/28/2002</AwardExpirationDate>
    <AwardAmount>400000</AwardAmount>
    <AwardInstrument>
      <Value>Standard Grant</Value>
    </AwardInstrument>
    <Organization>
      <Code>07070000</Code>
      <Directorate>
        <LongName>Directorate For Engineering</LongName>
      </Directorate>
      <Division>
        <LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
      </Division>
    </Organization>
    <ProgramOfficer>
      <SignBlockName>George B. Vermont</SignBlockName>
    </ProgramOfficer>
    <AbstractNarration>This Small Business Innovation Research Phase II project describes the&lt;br/&gt;development of a disposable, highly efficient suspension bioreactor for &lt;br/&gt;primary hematopoietic (blood cell-forming) cell culture. The unique &lt;br/&gt;challenges (heterogeneous nature, donor variability, and shear-sensitivity)&lt;br/&gt;of these cultures render traditional flask or suspension cultures unable to &lt;br/&gt;economically and consistently produce large quantities of cells. In Phase I, &lt;br/&gt;the feasibility and characteristics of a disposable suspension bioreactor was &lt;br/&gt;demonstrated. In Phase II, a scaled-up prototype of a large, agitated &lt;br/&gt;disposable bioreactor designed for clinical use (stem cell transplantation)&lt;br/&gt; will be constructed, characterized, and tested for reliability and durability. &lt;br/&gt;Gas and mass transfer correlations established in Phase I will be verified &lt;br/&gt;and extended. The use of medium optical density as a surrogate measure &lt;br/&gt;for cell density will be investigated.&lt;br/&gt;&lt;br/&gt;The final product will be a system that combines the simple, disposable nature &lt;br/&gt;of flask culture with the control and monitoring capabilities of a suspension &lt;br/&gt;bioreactor. The resulting system will enable the cost-effective production of &lt;br/&gt;large numbers of primary hematopoietic cells and will improve the effectiveness&lt;br/&gt;and decrease the cost of medical procedures in the fields of transplantation, &lt;br/&gt;immunotherapy, and gene therapy.</AbstractNarration>
    <MinAmdLetterDate>07/24/2000</MinAmdLetterDate>
    <MaxAmdLetterDate>07/24/2000</MaxAmdLetterDate>
    <ARRAAmount/>
    <AwardID>0078716</AwardID>
    <Investigator>
      <FirstName>Todd</FirstName>
      <LastName>McAdams</LastName>
      <EmailAddress>lcfarrar@resodyn.com</EmailAddress>
      <StartDate>07/24/2000</StartDate>
      <EndDate/>
      <RoleCode>Principal Investigator</RoleCode>
    </Investigator>
    <Institution>
      <Name>Tissue Therapeutics</Name>
      <CityName>Evanston</CityName>
      <ZipCode>602083120</ZipCode>
      <PhoneNumber>8474674559</PhoneNumber>
      <StreetAddress>2143 Sheridan Road</StreetAddress>
      <CountryName>United States</CountryName>
      <StateName>Illinois</StateName>
      <StateCode>IL</StateCode>
    </Institution>
    <FoaInformation>
      <Code>0308000</Code>
      <Name>Industrial Technology</Name>
    </FoaInformation>
    <ProgramElement>
      <Code>5373</Code>
      <Text>SMALL BUSINESS PHASE II</Text>
    </ProgramElement>
    <ProgramReference>
      <Code>1491</Code>
      <Text>BIOTECH, BIOCHEM &amp; BIOMASS ENG</Text>
    </ProgramReference>
    <ProgramReference>
      <Code>9181</Code>
      <Text>BIOPROCESSING/BIOMOLECULAR MATERIALS</Text>
    </ProgramReference>
    <ProgramReference>
      <Code>BIOT</Code>
      <Text>BIOTECHNOLOGY</Text>
    </ProgramReference>
  </Award>
</rootTag>
